These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

118 related items for PubMed ID: 7915367

  • 1. Efficacy of low-density-lipoprotein lowering with statins.
    Seidel D, Cremer P.
    Lancet; 1994 Sep 03; 344(8923):683. PubMed ID: 7915367
    [No Abstract] [Full Text] [Related]

  • 2. Efficacy of low-density-lipoprotein lowering with statins.
    Rosenson RS, Stein JH.
    Lancet; 1994 Sep 03; 344(8923):683. PubMed ID: 7915366
    [No Abstract] [Full Text] [Related]

  • 3. Defined daily doses in relation to hypolipidaemic efficacy of lovastatin, pravastatin, and simvastatin.
    Illingworth DR, Erkelens DW, Keller U, Thompson GR, Tikkanen MJ.
    Lancet; 1994 Jun 18; 343(8912):1554-5. PubMed ID: 7911877
    [No Abstract] [Full Text] [Related]

  • 4. Efficacy of low-density-lipoprotein lowering with statins.
    Leufkens HG, Herings RM, Urquhart J.
    Lancet; 1994 Sep 03; 344(8923):683-4. PubMed ID: 7915368
    [No Abstract] [Full Text] [Related]

  • 5. Efficacy of low-density-lipoprotein lowering with statins.
    Marshall S, Meredith PA, Elliott HL.
    Lancet; 1994 Sep 03; 344(8923):684. PubMed ID: 7915369
    [No Abstract] [Full Text] [Related]

  • 6. Consensus statement: Role of therapy with "statins" in patients with hypertriglyceridemia.
    Grundy SM.
    Am J Cardiol; 1998 Feb 26; 81(4A):1B-6B. PubMed ID: 9526806
    [No Abstract] [Full Text] [Related]

  • 7. A 16-week fenofibrate treatment increases LDL particle size in type IIA dyslipidemic patients.
    Lemieux I, Laperrière L, Dzavik V, Tremblay G, Bourgeois J, Després JP.
    Atherosclerosis; 2002 Jun 26; 162(2):363-71. PubMed ID: 11996956
    [Abstract] [Full Text] [Related]

  • 8. Subcutaneous administration of HMG-CoA reductase inhibitors in hyperlipidaemic and normal rats.
    Joles J, Willekes-Koolschijn N, Koomans H, Van Tol A, Geelhoed-Mieras T, Crommelin D, Van Bloois L, Krajnc-Franken M, Cohen L, Griffioen M.
    Lab Anim; 1992 Oct 26; 26(4):269-80. PubMed ID: 1447905
    [Abstract] [Full Text] [Related]

  • 9. [Cardiovascular pharmacology (VIII). The role of HMG CoA reductase inhibitors in the current treatment of hyperlipidemias].
    Carmena R.
    Rev Esp Cardiol; 1995 Jan 26; 48(1):59-65. PubMed ID: 7878284
    [No Abstract] [Full Text] [Related]

  • 10. [Use of hydroxymethylglutaryl coenzyme A reductase inhibitors in patients with post-transplantation hyperlipemia].
    Martínez-Castelao A.
    Med Clin (Barc); 1995 Nov 25; 105(18):719. PubMed ID: 8538262
    [No Abstract] [Full Text] [Related]

  • 11. [Which statin is more efficient? Concepts and applications in economic evaluation].
    García-Altés A, Jovell AJ.
    Aten Primaria; 2000 Sep 30; 26(5):333-8. PubMed ID: 11100606
    [No Abstract] [Full Text] [Related]

  • 12. [Efficacy and safety of simvastatin in the treatment of hyperlipidemia in uremic patients undergoing hemodialysis treatment].
    Fiorini F, Patrone E, Ardu F, Castelluccio A.
    Minerva Urol Nefrol; 1992 Sep 30; 44(2):165-8. PubMed ID: 1411867
    [Abstract] [Full Text] [Related]

  • 13. Statins and fibrates in the management of diabetic dyslipidemia.
    Durrington P.
    Diabet Med; 1997 Jul 30; 14(7):513-6. PubMed ID: 9223386
    [No Abstract] [Full Text] [Related]

  • 14. Effects of simvastatin, an HMG-CoA reductase inhibitor, on plasma lipids and steroid hormones.
    Ide H, Fujiya S, Aanuma Y, Agishi Y.
    Clin Ther; 1990 Jul 30; 12(5):410-20. PubMed ID: 2268863
    [Abstract] [Full Text] [Related]

  • 15. Reducing expenditures for statin-type lipid-lowering agents.
    Am J Health Syst Pharm; 1998 May 15; 55(10):995-6, 999. PubMed ID: 9606450
    [No Abstract] [Full Text] [Related]

  • 16. Lipid-lowering with statins and fibrinolytic parameters.
    Jovin IS, Heidinger K, Taborski U, Muller-Berghaus G.
    Eur Heart J; 1997 Sep 15; 18(9):1516. PubMed ID: 9458463
    [No Abstract] [Full Text] [Related]

  • 17. Efficacy of three statins at lower maintenance doses.
    Carr-Lopez S, Exstrum T, Morse T, Shepherd M, Bush AC.
    Clin Ther; 1999 Feb 15; 21(2):331-9. PubMed ID: 10211536
    [Abstract] [Full Text] [Related]

  • 18. Low-density lipoprotein cholesterol (LDL-C) levels and LDL-C goal attainment among elderly patients treated with rosuvastatin compared with other statins in routine clinical practice.
    Harley CR, Gandhi S, Blasetto J, Heien H, Sasane R, Nelson SP.
    Am J Geriatr Pharmacother; 2007 Sep 15; 5(3):185-94. PubMed ID: 17996658
    [Abstract] [Full Text] [Related]

  • 19. The rule of 5 and the rule of 7 in lipid-lowering by statin drugs.
    Roberts WC.
    Am J Cardiol; 1997 Jul 01; 80(1):106-7. PubMed ID: 9205036
    [No Abstract] [Full Text] [Related]

  • 20. Effectiveness of high doses of simvastatin as monotherapy in mixed hyperlipidemia.
    Miller M, Dolinar C, Cromwell W, Otvos JD.
    Am J Cardiol; 2001 Jan 15; 87(2):232-4, A9. PubMed ID: 11152850
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 6.